down arrow

Spyre Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00773J2024
USD
32.03
-2.06 (-6.03%)

Jan 23

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

31.7734.47

52 Week

10.9135.31
Valuation
Technical
Day's Volume

CASH

407.77 k

Shareholding (Sep 2025)

FII

7.37%

Held by 72 FIIs

DII

59.73%

Held by 36 DIIs

Promoter

4.84%

How big is Spyre Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Spyre Therapeutics, Inc. has a market capitalization of 916.17 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -160.22 million over the latest four quarters.

Market Cap: As of Jun 18, Spyre Therapeutics, Inc. has a market capitalization of 916.17 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Spyre Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -160.22 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 517.80 million and total assets of 608.48 million.

View full answer

What does Spyre Therapeutics, Inc. do?

22-Jun-2025

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing enzyme therapeutics for rare diseases, with a market cap of approximately $916.17 million and a recent net profit of -$36 million. The company is classified as a micro-cap and has no dividend yield.

Overview:<BR>Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing human enzyme therapeutics for rare and high-burden diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -36 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 916.17 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.17 <BR>Return on Equity: -33.70% <BR>Price to Book: 1.90<BR><BR>Contact Details:<BR>Address: 805 Las Cimas Parkway, Suite 100, AUSTIN TX: 78746 <BR>Tel: ['1 512 9422935', '1 512 9003661'] <BR>Fax: 1 512 8725121 <BR>Website: http://aegleabio.com

View full answer

Who are in the management team of Spyre Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Spyre Therapeutics, Inc. includes Mr. Russell Cox (Independent Chairman), Dr. Anthony Quinn (President and CEO), and several independent directors: Ms. Alison Lawton, Dr. Suzanne Bruhn, Dr. V. Bryan Lawlis, Dr. Ivana Magovcevic-Liebisch, and Mr. Sandesh Mahatme. This team combines executive leadership with independent oversight.

As of March 2022, the management team of Spyre Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Russell Cox, who serves as the Independent Chairman of the board.<BR>- Dr. Anthony Quinn, who is the President and Chief Executive Officer, as well as a Director.<BR>- Ms. Alison Lawton, who is a Director.<BR>- Dr. Suzanne Bruhn, who is an Independent Director.<BR>- Dr. V. Bryan Lawlis, who is also an Independent Director.<BR>- Dr. Ivana Magovcevic-Liebisch, who serves as an Independent Director.<BR>- Mr. Sandesh Mahatme, who is another Independent Director. <BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance of the company.

View full answer

Is Spyre Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of February 29, 2024, Spyre Therapeutics, Inc. is considered overvalued and has deteriorated to a "does not qualify" valuation grade due to negative financial metrics, including a Price to Book Value of 2.12, an EV to EBIT of -2.14, and a Return on Equity of -33.70%, alongside poor stock performance and unfavorable comparisons to its peers.

As of 29 February 2024, the valuation grade for Spyre Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently deemed overvalued given its negative financial metrics, including a Price to Book Value of 2.12 and an EV to EBIT of -2.14. Additionally, the Return on Equity (ROE) stands at a concerning -33.70%, reflecting ongoing losses and a lack of profitability.<BR><BR>In comparison to its peers, Spyre Therapeutics shows a stark contrast with companies like BioCryst Pharmaceuticals, which has a P/E ratio of -39.02, and AbCellera Biologics, with an EV to EBITDA of -1.35. These peers also reflect a risky valuation, but Spyre's metrics suggest it is not positioned favorably within this group. The recent stock performance has been poor, with a year-to-date return of -36.94%, significantly underperforming the S&P 500, which has returned 2.44% in the same period. Overall, Spyre Therapeutics is considered overvalued based on its current financial ratios and peer comparisons.

View full answer

Is Spyre Therapeutics, Inc. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Spyre Therapeutics, Inc. shows a bullish technical trend with strong weekly indicators, having outperformed the S&P 500 recently, although its year-to-date return lags behind the index.

As of 24 October 2025, the technical trend for Spyre Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The weekly Bollinger Bands and KST are bullish, while the monthly Bollinger Bands and KST are mildly bearish. The Dow Theory shows a mildly bullish trend on both weekly and monthly time frames. <BR><BR>In terms of performance, Spyre Therapeutics has outperformed the S&P 500 over the past week and month, returning 4.01% and 37.47% respectively, while the S&P 500 returned 1.92% and 2.32%. However, the year-to-date return is only 0.39%, significantly lagging behind the S&P 500's 15.47%. Overall, the current technical stance is bullish, driven by strong weekly indicators despite some mixed monthly signals.

View full answer

Compare Spyre Therapeutics, Inc. with Similar Stocks

Vir Biotechnology, Inc.Summit Therapeutics, Inc.Rhythm Pharmaceuticals, Inc.
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,637 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.07

stock-summary
Return on Equity

-37.32%

stock-summary
Price to Book

5.80

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-37 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
43.21%
0%
43.21%
6 Months
79.87%
0%
79.87%
1 Year
46.88%
0%
46.88%
2 Years
17.0%
0%
17.0%
3 Years
6121.6%
0%
6121.6%
4 Years
641.55%
0%
641.55%
5 Years
-83.21%
0%
-83.21%

Spyre Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Is Spyre Therapeutics, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Spyre Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The weekly Bollinger Bands and KST are bullish, while the monthly Bollinger Bands and KST are mildly bearish. The Dow Theory shows a mildly bullish trend on both weekly and monthly time frames. In terms of performance, Spyre Therapeutics has outperformed the S&P 500 over the past week and month, returning 4.01% and 37.47% respectively, while the S&P 500 returned 1.92% and 2.32%. However, the year-to-date return is only 0.39%, significantly lagging behind the S&P 500's 15.47%. Overall, the current technical stance is bullish, driven by strong weekly indicators despite some mixed monthly signals....

Read full news article

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-191.02%
EBIT to Interest (avg)
-109.06
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.17
Sales to Capital Employed (avg)
-0.05
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
96.25%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.12
EV to EBIT
-2.14
EV to EBITDA
-2.14
EV to Capital Employed
-5.59
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-33.70%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 41 Schemes (28.07%)

Foreign Institutions

Held by 72 Foreign Institutions (7.37%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -1.66% vs 17.39% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-51.90",
          "val2": "-53.60",
          "chgp": "3.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "2.40",
          "chgp": "-125.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-36.70",
          "val2": "-36.10",
          "chgp": "-1.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -60.87% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -57.64% vs -13.25% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.90",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-208.60",
          "val2": "-116.60",
          "chgp": "-78.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-224.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-149.60",
          "val2": "-94.90",
          "chgp": "-57.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-132,744.90%",
          "chgp": "13,274.49%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary

Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-51.90
-53.60
3.17%
Interest
0.00
0.00
Exceptional Items
-0.60
2.40
-125.00%
Consolidate Net Profit
-36.70
-36.10
-1.66%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -1.66% vs 17.39% in Mar 2025

All Quarterly Resultsstock-summary

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.90
-100.00%
Operating Profit (PBDIT) excl Other Income
-208.60
-116.60
-78.90%
Interest
0.00
0.00
Exceptional Items
0.00
-224.70
100.00%
Consolidate Net Profit
-149.60
-94.90
-57.64%
Operating Profit Margin (Excl OI)
0.00%
-132,744.90%
13,274.49%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -60.87% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -57.64% vs -13.25% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Spyre Therapeutics, Inc. stock-summary
stock-summary
Spyre Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a human enzyme therapeutics as advanced solutions for rare and other high-burden diseases. The Company’s product candidates are Pegzilarginase, ACN00177 and AEB5100. Its Pegzilarginase is a recombinant human Arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase One Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its ACN00177 is a PEGylated or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria.
Company Coordinates stock-summary
Company Details
805 Las Cimas Parkway, Suite 100 , AUSTIN TX : 78746
stock-summary
Tel: 1 512 94229351 512 9003661
stock-summary
http://aegleabio.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."